MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Stoke Therapeutics Total Liabilities 2011-2026 | STOK
Annual Total Liabilities Stoke Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.8 M | 71.2 M | 21.1 M | 11.8 M | 4.32 M | 2.47 M | 3.73 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.2 M | 2.47 M | 26.2 M |
Quarterly Total Liabilities Stoke Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.2 M | 49.6 M | 56.8 M | 42.5 M | 61.2 M | 65 M | 64.8 M | 68.8 M | 66.9 M | 66.7 M | 68 M | 71.2 M | 73.5 M | 77.1 M | 76 M | 21.1 M | 16.3 M | 9.38 M | 6.44 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 4.32 M | 4.32 M | 4.32 M | 4.32 M | 2.47 M | 2.47 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.1 M | 2.47 M | 36.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
705 M | $ 20.7 | -1.24 % | $ 2.61 B | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.84 | 7.59 % | $ 4.58 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 166.38 | 1.52 % | $ 8.28 B | USA |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.82 | 5.82 % | $ 1.14 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.73 | 3.44 % | $ 1.37 B | Britain |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 26.86 | -3.83 % | $ 719 M | USA |
 |
Codexis
CDXS
|
82.1 M | $ 1.02 | 0.99 % | $ 74.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.8 | -2.06 % | $ 116 M | France |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
CNS Pharmaceuticals
CNSP
|
2.52 M | $ 3.13 | -0.95 % | $ 1.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Collegium Pharmaceutical
COLL
|
1.36 B | $ 41.6 | -0.17 % | $ 1.32 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 35.97 | 0.76 % | $ 3.74 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
150 M | $ 23.88 | 3.47 % | $ 2.92 B | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
35.2 M | $ 8.35 | -2.57 % | $ 36.1 M | USA |
 |
Curis
CRIS
|
47.3 M | $ 1.08 | -5.26 % | $ 6.81 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
134 M | $ 40.68 | -1.02 % | $ 3.83 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 17.89 | -2.03 % | $ 859 M | USA |
 |
Champions Oncology
CSBR
|
28.6 M | $ 6.07 | 2.71 % | $ 82.9 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
42.5 M | $ 0.72 | -2.3 % | $ 4.84 M | USA |
 |
CEL-SCI Corporation
CVM
|
14.1 M | $ 3.83 | -10.09 % | $ 244 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Daré Bioscience
DARE
|
28.1 M | $ 1.61 | -5.29 % | $ 13.7 M | USA |
 |
DBV Technologies S.A.
DBVT
|
38.3 M | $ 23.25 | 10.77 % | $ 2.26 B | France |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Precision BioSciences
DTIL
|
141 M | $ 4.33 | 3.1 % | $ 16.6 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
387 M | $ 3.34 | 0.3 % | $ 1.2 M | USA |
 |
Dyadic International
DYAI
|
2.34 M | $ 0.77 | -1.68 % | $ 22.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Editas Medicine
EDIT
|
207 M | $ 2.15 | -2.27 % | $ 177 M | USA |
 |
Edesa Biotech
EDSA
|
1.83 M | $ 2.28 | 3.64 % | $ 7.29 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
104 M | $ 29.2 | -3.41 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Equillium
EQ
|
28 M | $ 1.92 | 5.49 % | $ 66.7 M | USA |